White Paper

Adeno-Associated Virus (AAV)
Vectors Manufacturing

Get White Paper
White paper

What Are the Challenges and Solutions?

All across the globe, AAVs are getting the attention of scientists and companies working in gene therapy, as they provide the right combination of characteristics that make them the most promising vector today. In 2021 only, the global gene therapy market was 4.1 billion USD, and AAV vector therapies made up more than 43% of that market value!

Designing and manufacturing AAV vectors is complex, and to be successful, certain challenges must be addressed. This implies monitoring and optimizing production for a thorough quality control process, including reliable ongoing characterization of process intermediates and the final product.

Key features include:

  • Overview and data on the gene therapy market
  • Description of AAV vectors’ genomes and transfer
  • Challenges associated with AAV vectors’ design and manufacturing
  • Analytical methods for AAV vector quality control with a description of innovative no-wash AlphaLISA® assays

Download this White Paper

We are committed to your privacy. Cisbio needs the contact information you provide us to keep you aware about relevant content, products, and services. You may unsubscribe from these communications at any time. For more information check out our  Privacy Policy.

PerkinElmer and Cisbio logo